Human Papillomavirus Vaccination in Tanzanian Schoolgirls: Cluster-Randomized Trial Comparing 2 Vaccine-Delivery Strategies

被引:63
|
作者
Watson-Jones, Deborah [1 ,3 ]
Baisley, Kathy
Ponsiano, Riziki [3 ]
Lemme, Francesca [3 ]
Remes, Pieter [2 ,3 ]
Ross, David
Kapiga, Saidi [3 ]
Mayaud, Philippe
de Sanjose, Silvia [5 ,6 ]
Wight, Daniel [2 ]
Changalucha, John [4 ]
Hayes, Richard
机构
[1] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England
[2] MRC, Social & Publ Hlth Sci Unit, Glasgow, Lanark, Scotland
[3] Mwanza Intervent Trials Unit, Mwanza, Tanzania
[4] Natl Inst Med Res, Mwanza, Tanzania
[5] Inst Catala Oncol, IDIBELL, Canc Epidemiol Res Programme, Unit Infect & Canc, Barcelona, Spain
[6] CIBER Epidemiol & Salud Publ, Barcelona, Spain
来源
JOURNAL OF INFECTIOUS DISEASES | 2012年 / 206卷 / 05期
基金
英国惠康基金;
关键词
D O I
10.1093/infdis/jis407
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. We compared vaccine coverage achieved by 2 different delivery strategies for the quadrivalent human papillomavirus (HPV) vaccine in Tanzanian schoolgirls. Methods.In a cluster-randomized trial of HPV vaccination conducted in Tanzania, 134 primary schools were randomly assigned to class-based (girls enrolled in primary school grade [class] 6) or age-based (girls born in 1998; 67 schools per arm) vaccine delivery. The primary outcome was coverage by dose. Results.There were 3352 and 2180 eligible girls in schools randomized to class-based and age-based delivery, respectively. HPV vaccine coverage was 84.7% for dose 1, 81.4% for dose 2, and 76.1% for dose 3. For each dose, coverage was higher in class-based schools than in age-based schools (dose 1: 86.4% vs 82.0% [P = .30]; dose 2: 83.8% vs 77.8% [P = .05]; and dose 3: 78.7% vs 72.1% [P = .04]). Vaccine-related adverse events were rare. Reasons for not vaccinating included absenteeism (6.3%) and parent refusal (6.7%). School absenteeism rates prior to vaccination ranged from 8.1% to 23.5%. Conclusions.HPV vaccine can be delivered with high coverage in schools in sub-Saharan Africa. Compared with age-based vaccination, class-based vaccination located more eligible pupils and achieved higher coverage. HPV vaccination did not increase absenteeism rates in selected schools. Innovative strategies will be needed to reach out-of-school girls. Clinical Trials Registration. NCT01173900.
引用
收藏
页码:678 / 686
页数:9
相关论文
共 50 条
  • [31] Integrating research into routine service delivery in an antiretroviral treatment programme: lessons learnt from a cluster randomized trial comparing strategies of HIV care in Jinja, Uganda
    Jaffar, Shabbar
    Amuron, Barbara
    Birungi, Josephine
    Namara, Geoffrey
    Nabiryo, Christine
    Coutinho, Alex
    Grosskurth, Heiner
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2008, 13 (06) : 795 - 800
  • [32] Implementation of a provider-focused intervention for maximizing human papillomavirus (HPV) vaccine uptake in young cancer survivors receiving follow-up care in pediatric oncology practices: protocol for a cluster-randomized trial of the HPV PROTECT intervention
    Wendy Landier
    Smita Bhatia
    Joshua S. Richman
    Paula D. Campos Gonzalez
    Brooke Cherven
    Veronica Chollette
    Jamie Aye
    Sharon M. Castellino
    Maria M. Gramatges
    Susan Lindemulder
    Thomas B. Russell
    Lucie M. Turcotte
    Graham A. Colditz
    Melissa B. Gilkey
    James L. Klosky
    BMC Pediatrics, 22
  • [33] Effects of different educational interventions on cervical cancer knowledge and human papillomavirus vaccination uptake among young women in Japan: Preliminary results of a cluster randomized controlled trial
    Takahashi, Yuko
    Sasamori, Yukifumi
    Higuchi, Risa
    Kaku, Asumi
    Kumagai, Tomoo
    Watanabe, Saya
    Nishizawa, Miki
    Takasaki, Kazuki
    Nishida, Haruka
    Ichinose, Takayuki
    Hirano, Mana
    Miyagawa, Yuko
    Hiraike, Haruko
    Kido, Koichiro
    Ishikawa, Hirono
    Nagasaka, Kazunori
    PLOS ONE, 2025, 20 (01):
  • [34] Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine:: Infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination
    Vandepapelière, P
    Barrasso, R
    Meijer, CJLM
    Walboomers, JMM
    Wettendorff, M
    Stanberry, LR
    Lacey, CJN
    JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (12): : 2099 - 2107
  • [35] Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial
    Donken, Robine
    Dobson, Simon R. M.
    Marty, Kim D.
    Cook, Darrel
    Sauvageau, Chantal
    Gilca, Vladimir
    Dionne, Marc
    McNeil, Shelly
    Krajden, Mel
    Money, Deborah
    Kellner, James
    Scheifele, David W.
    Kollmann, Tobias
    Bettinger, Julie A.
    Liu, Shuzhen
    Singer, Joel
    Naus, Monika
    Sadarangani, Manish
    Ogilvie, Gina S.
    CLINICAL INFECTIOUS DISEASES, 2020, 71 (04) : 1022 - 1029
  • [36] Phase I and II randomized clinical trial of an oral therapeutic vaccine targeting human papillomavirus for treatment of cervical intraepithelial neoplasia 2 and 3
    Kawana, Kei
    Kobayashi, Osamu
    Ikeda, Yuji
    Yahata, Hideaki
    Iwata, Takashi
    Satoh, Toyomi
    Akiyama, Azusa
    Maeda, Daichi
    Hori-Hirose, Yumiko
    Uemura, Yukari
    Nakayama-Hosoya, Kaori
    Katoh, Kanoko
    Katoh, Yuki
    Nakajima, Takahiro
    Taguchi, Ayumi
    Komatsu, Atsushi
    Asai-Sato, Mikiko
    Tomita, Naoko
    Kato, Kiyoko
    Aoki, Daisuke
    Igimi, Shizunobu
    Kawana-Tachikawa, Ai
    Schust, Danny J.
    JNCI CANCER SPECTRUM, 2023, 7 (06)
  • [37] Evaluating the impact of multilevel evidence-based implementation strategies to enhance provider recommendation on human papillomavirus vaccination rates among an empaneled primary care patient population: a study protocol for a stepped-wedge cluster randomized trial
    Lila J. Finney Rutten
    Carmen Radecki Breitkopf
    Jennifer L. St. Sauver
    Ivana T. Croghan
    Debra J. Jacobson
    Patrick M. Wilson
    Jeph Herrin
    Robert M. Jacobson
    Implementation Science, 13
  • [38] Evaluating the impact of multilevel evidence-based implementation strategies to enhance provider recommendation on human papillomavirus vaccination rates among an empaneled primary care patient population: a study protocol for a stepped-wedge cluster randomized trial
    Rutten, Lila J. Finney
    Breitkopf, Carmen Radecki
    St Sauver, Jennifer L.
    Croghan, Ivana T.
    Jacobson, Debra J.
    Wilson, Patrick M.
    Herrin, Jeph
    Jacobson, Robert M.
    IMPLEMENTATION SCIENCE, 2018, 13
  • [39] HEPATITIS-B VACCINATION OF HEMODIALYSIS-PATIENTS - RANDOMIZED CONTROLLED TRIAL COMPARING PLASMA-DERIVED VACCINE WITH AND WITHOUT PRE-S2 ANTIGEN
    SMITLEIJS, MBL
    KRAMER, P
    HEIJTINK, RA
    HOP, WCJ
    SCHALM, SW
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1990, 20 (05) : 540 - 545
  • [40] Immunogenicity and safety of an E. coli-produced bivalent human papillomavirus (type 16 and 18) vaccine: A randomized controlled phase 2 clinical trial
    Wu, Ting
    Hu, Yue-Mei
    Li, Juan
    Chu, Kai
    Huang, Shou-Jie
    Zhao, Hui
    Wang, Zhong-Ze
    Yang, Chang-Lin
    Jiang, Han-Min
    Wang, Yi-Jun
    Lin, Zhi-Jie
    Pan, Hui-Rong
    Sheng, Wei
    Wei, Fei-Xue
    Li, Shao-Wei
    Wang, Ying
    Zhu, Feng-Cai
    Li, Chang-Gui
    Zhang, Jun
    Xia, Ning-Shao
    VACCINE, 2015, 33 (32) : 3940 - 3946